AIM ImmunoTech (AIM) 10-Q 8 Nov 13 2013 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2013	Nov. 01, 2013
Document and Entity Information	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-13	'
Document Fiscal Period Focus	'Q3	'
Document Fiscal Year Focus	'2013	'
Entity Registrant Name	'HEMISPHERX BIOPHARMA INC	'
Entity Central Index Key	'0000946644	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding (shares)	'	167,686,551

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$1,598	$2,212
Marketable securities – unrestricted	13,555	27,241
Marketable securities – restricted	14,068	14,500
Inventories	0	453
Prepaid expenses and other current assets	332	322
Total current assets	29,553	44,728
Property and equipment, net	5,145	5,292
Patent and trademark rights, net	1,074	1,034
Construction in progress	6,970	6,580
Other assets	136	65
Total assets	42,878	57,699
Current liabilities:	'	'
Accounts payable	1,723	2,157
Accrued expenses	1,822	3,395
Margin account loan	7,051	7,051
Current portion of capital lease	34	46
Total current liabilities	10,630	12,649
Long-term liabilities	'	'
Long-term portion of capital lease	31	55
Redeemable warrants	66	295
Total liabilities	10,727	12,999
Commitments and contingencies	'	'
Stockholders’ equity:	'	'
Preferred stock, par value $0.01 per share, authorized 5,000,000; issued and outstanding; none	0	0
Common stock, par value $0.001 per share, authorized 350,000,000 shares; issued and outstanding 167, 551,959 and 166,490,190, respectively	167	166
Additional paid-in capital	289,199	288,671
Accumulated other comprehensive loss	-91	-43
Accumulated deficit	-257,124	-244,094
Total stockholders’ equity	32,151	44,700
Total liabilities and stockholders’ equity	$42,878	$57,699

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Statement of Financial Position [Abstract]	'	'
Preferred stock, par value per share (usd per share)	$0.01	$0.01
Preferred stock, authorized shares	5,000,000	5,000,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value (usd per share)	$0.00	$0.00
Common stock, authorized shares	350,000,000	350,000,000
Common stock, issued	167,551,959	166,490,190
Common stock, outstanding	167,551,959	166,490,190

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Loss (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Revenues:	'	'	'	'
Clinical treatment programs	$36	$39	$114	$160
Total revenues	36	39	114	160
Costs and expenses:	'	'	'	'
Production/cost of goods sold	252	988	1,078	1,476
Research and development	2,173	2,357	6,827	5,758
General and administrative	2,070	1,659	5,964	5,271
Total costs and expenses	4,495	5,004	13,869	12,505
Operating loss	-4,459	-4,965	-13,755	-12,345
Interest expense	-4	-7	-14	-19
Interest and other income	89	353	624	873
Other than temporary impairment loss on marketable securities	-800	0	-800	0
Funds received from sale of income tax net operating losses	0	0	686	1,328
Redeemable warrants valuation adjustment	38	-1,968	229	-1,732
Net loss	-5,136	-6,587	-13,030	-11,895
Other Comprehensive Income (Loss):	'	'	'	'
Unrealized gain (loss) on marketable securities	867	306	-93	890
Realized gain (loss) on marketable securities	131	-168	44	-205
Less: Premium amortization	-1	24	1	132
Net comprehensive loss	($4,139)	($6,425)	($13,078)	($11,078)
Basic and diluted loss per share (usd per share)	($0.03)	($0.05)	($0.08)	($0.09)
Weighted average shares outstanding, basic and diluted (shares)	167,389,685	137,012,240	167,135,111	136,260,727

Consolidated_Statements_of_Cha

Consolidated Statements of Changes in Stockholders' Equity and Comprehensive Income (Loss) (USD $)	Total	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Deficit [Member]
In Thousands, except Share data, unless otherwise specified
Balance at Dec. 31, 2012	$44,700	$166	$288,671	($43)	($244,094)
Balance, Common Stock Shares (shares) at Dec. 31, 2012	'	166,490,190	'	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'
Stock issued for settlement of accounts payable, Common Stock Shares (shares)	'	1,061,769	'	'	'
Stock issued for settlement of accounts payable	237	1	236	'	'
Equity-based compensation	292	'	292	'	'
Net comprehensive loss	-13,078	'	'	-48	-13,030
Balance at Sep. 30, 2013	$32,151	$167	$289,199	($91)	($257,124)
Balance, Common Stock Shares (shares) at Sep. 30, 2013	'	167,551,959	'	'	'

Consolidated_Statements_of_Cha1

Consolidated Statements of Changes in Stockholders' Equity and Comprehensive Income (Loss) (Parenthetical) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Statement of Stockholders' Equity [Abstract]	'	'
Common stock, par value (usd per share)	$0.00	$0.00

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012
Cash flows from operating activities:	'	'
Net loss	($13,030)	($11,895)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation of property and equipment	504	469
Amortization of patent and trademark rights	144	29
Redeemable warrants valuation adjustment	-229	1,732
Equity-based compensation	292	195
Change in assets and liabilities:	'	'
Inventories	453	98
Prepaid expenses and other current assets	-10	274
Accounts payable	-197	925
Accrued expenses	-1,573	-8
Net cash used in operating activities	-13,646	-8,181
Cash flows from investing activities:	'	'
Purchase of property, equipment and construction in progress	-747	-4,821
Additions to patent and trademark rights	-184	-113
Deposits on capital leases refunded	3	6
Prepaid expenses and other current assets	-74	0
Maturities of short-term and long-term marketable securities	14,070	13,380
Purchase of short-term and long-term marketable securities	0	-13,515
Net cash provided by (used in) investing activities	13,068	-5,063
Cash flows from financing activities:	'	'
Payments on capital leases	-36	-35
Proceeds from margin account loan	0	4,066
Proceeds from sale of stock, net of issuance costs	0	9,268
Net cash provided by (used in) financing activities	-36	13,299
Net increase (decrease) in cash and cash equivalents	-614	55
Cash and cash equivalents at beginning of period	2,212	3,103
Cash and cash equivalents at end of period	1,598	3,158
Supplemental disclosures of non-cash investing and financing cash flow information:	'	'
Issuance of common stock for accounts payable and accrued expenses	237	262
Unrealized gain (loss) on marketable securities	-93	890
Redeemable warrants valuation adjustment	-229	1,732
Supplemental disclosure of cash flow information:	'	'
Cash paid for interest expense and capitalized construction interest	($144)	($68)

Basis_Of_Presentation

Basis Of Presentation	9 Months Ended
	Sep. 30, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Basis Of Presentation	'
	Basis Of Presentation
	The consolidated financial statements include the financial statements of Hemispherx Biopharma, Inc. and its wholly-owned subsidiaries. The Company has three domestic subsidiaries: BioPro Corp., BioAegean Corp. and Core Biotech Corp., all of which are incorporated in Delaware and are dormant. The Company’s foreign subsidiary, Hemispherx Biopharma Europe N.V./S.A., established in Belgium in 1998, has minimal activity. All significant intercompany balances and transactions have been eliminated in consolidation.
	In the opinion of Management, all adjustments necessary for a fair presentation of such consolidated financial statements have been included. Such adjustments consist of normal recurring items. Interim results are not necessarily indicative of results for a full year.
	The interim consolidated financial statements and notes thereto are presented as permitted by the Securities and Exchange Commission (“SEC”), and do not contain certain information which will be included in the Company’s annual consolidated financial statements and notes thereto.
	These consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements for the years ended December 31, 2012 and 2011, contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2012.

Net_Loss_Per_Share

Net Loss Per Share	9 Months Ended
	Sep. 30, 2013
Earnings Per Share [Abstract]	'
Net Loss Per Share	'
	Net Loss Per Share
	Basic and diluted net loss per share is computed using the weighted average number of shares of common stock outstanding during the period. Equivalent common shares, consisting of stock options and warrants which amounted to 38,421,415 and 33,348,458 shares for the nine months ended September 30, 2013 and 2012, respectively, are excluded from the calculation of diluted net loss per share since their effect is anti-dilutive.

EquityBased_Compensation

Equity-Based Compensation	9 Months Ended
	Sep. 30, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Equity-Based Compensation	'
	Equity-Based Compensation
	The fair value of each option award is estimated on the date of grant using a Black-Scholes-Merton option valuation model. Expected volatility is based on the historical volatility of the price of the Company’s stock. The risk-free interest rate is based on U.S. Treasury issues with a term equal to the expected life of the option. The Company uses historical data to estimate expected dividend yield, expected life and forfeiture rates. Accordingly, the fair values of the options granted, were estimated based on the following weighted average assumptions:
		Nine Months Ended September 30,
		2013		2012
	Risk-free interest rate	0.14% - 1.40%		0.68% - 0.86%
	Expected dividend yield	—		—
	Expected lives	1 year - 5 years		5.0 years
	Expected volatility	89.727% - 118.222%		108.76% - 111.95%
	Weighted average grant date fair value for options and warrants issued	$0.14 per option/warrant for 3,870,000 options / warrants		$0.23 per option for 1,499,000 options
	Stock option for employees' activity during the nine months ended September 30, 2013 is as follows:
	Stock option activity for employees:
		Number of			Weighted		Weighted	Aggregate
		Options			Average		Average	Intrinsic
					Exercise		Remaining	Value
					Price		Contractual
							Term
							(Years)
	Outstanding January 1, 2013	9,441,480			$	1.9	5.35	$	—
	Granted	1,170,000			0.36		9.74	—
	Forfeited	—			—		—	—
	Outstanding September 30, 2013	10,611,480			$	1.73	5.17	$	—
	Vested and expected to vest September 30, 2013	10,611,480			$	1.73	5.17	$	—
	Exercisable September 30, 2013	9,798,980			$	1.84	5.02	$	—
	1,170,000 options to purchase shares were granted to employees during the nine months ended September 30, 2013.
	Unvested stock option activity for employees:
		Number of			Weighted		Average	Aggregate
		Options			Average		Remaining	Intrinsic
					Exercise		Contractual	Value
					Price		Term
							(Years)
	Outstanding January 1, 2013	516,373			$	0.45	9.43	$	—
	Granted	882,500			0.27		9.4	—
	Vested	(586,373	)		0.43		9.26	—
	Forfeited	—			—		—	—
	Outstanding September 30, 2013	812,500			$	0.27	8.87	$	—
	Stock option activity for non-employees:
		Number of			Weighted		Weighted	Aggregate
		Options			Average		Average	Intrinsic
					Exercise		Remaining	Value
					Price		Contractual
							Term (Years)
	Outstanding January 1, 2013	3,428,432			$	1.73	4.71	$	—
	Granted	600,000			0.69		9.69	—
	Exercised	—			—		—	—
	Forfeited	(150,000	)		2		—	—
	Outstanding September 30, 2013	3,878,432			$	1.56	5	$	—
	Vested and expected to vest September 30, 2013	3,878,432			$	1.56	5	$	—
	Exercisable September 30, 2013	3,503,432			$	1.93	4.57	$	—
	600,000 options to purchase shares were granted to non-employees during the nine months ended September 30, 2013.
	Unvested stock option activity for non-employees during the year:
		Number of			Weighted		Weighted	Aggregate
		Options			Average		Average	Intrinsic
					Exercise		Remaining	Value
					Price		Contractual
							Term
							(Years)
	Outstanding January 1, 2013	210,422			$	0.4	9.68	$	—
	Options granted	375,000			0.25		9.75	—
	Options vested	(210,422	)		0.4		9.68	—
	Options forfeited	—			—		—	—
	Outstanding September 30, 2013	375,000			$	0.25	9.75	$	—
	The impact on the Company’s results of operations of recording equity-based compensation for the nine months ended September 30, 2013 and 2012 was to increase general and administrative expenses by approximately $292,000 and $195,000, respectively. The impact on basic and fully diluted earnings per share for the nine months ended September 30, 2013 and 2012 was $0.00 and $0.00, respectively.
	As of September 30, 2013 and 2012, respectively, there was $492,000 and $308,000 of unrecognized equity-based compensation cost related to options granted under the Equity Incentive Plan.

Inventories

Inventories	9 Months Ended
	Sep. 30, 2013
Inventory Disclosure [Abstract]	'
Inventories	'
	Inventories
	The Company uses the lower of first-in, first-out (“FIFO”) cost or market method of accounting for inventory.
	Inventories consist of the following:	(in thousands)
		September 30,			December 31,
		2013			2012
	Inventory work-in-process, January 1	$	453		$	897
	Production	5			579
	Spoilage	(458		)	(1,023		)
	Inventory work-in-process, end of period	$	—		$	453
	As of December 31, 2012, all of our lots of Alferon® Work-In-Process Inventory had completed the fill, finish and packaging process. The inventory would not be classified as Finished Goods until stability and release testing were concluded and it is confirmed by the U.S. Food and Drug Administration ("FDA") that the product could be commercially sold as is.
	In April 2012, FDA reviewers raised certain questions about the status of our existing lots of older Work-In-Process Alferon® materials and Alferon® Active Pharmaceutical Ingredient (“API”), which would need to be released by the FDA before those materials could be used in commercial product. After conducting all of the appropriate tests on samples of the inventory during 2013, the Company concluded that it could not alleviate certain questions the FDA had about the older Work-In-Process Alferon N Injection®. Accordingly, these lots will not be submitted to the FDA to request release for commercial sale and their remaining dollar value has been written-off in the quarter ended June 30, 2013.

Marketable_Securities_Unrestri

Marketable Securities - Unrestricted	9 Months Ended
	Sep. 30, 2013
Marketable Securities [Abstract]	'
Marketable Securities - Unrestricted	'
	Marketable Securities - Unrestricted
	Marketable securities consist of fixed income securities with remaining maturities of greater than three months at the date of purchase, debt securities and equity securities. As of September 30, 2013, it was determined that two of the marketable securities had other-than-temporary impairments and a loss of $300,000 was recognized. At September 30, 2013, all securities were classified as available for sale investments and were measured as Level 1 instruments of the fair value measurements standard (see "Note 11: Fair Value").
	Securities classified as available for sale consisted of:
	30-Sep-13
	(in thousands)
	Securities	Amortized			Gross			Gross				Fair Value			Short-Term			Long Term
		Cost			Unrealized			Unrealized							Investments			Investments
					Gains			Losses
	Mutual Funds	$	13,613		$	—		$	(58	)		$	13,555		$	13,555		$	—
	Totals	$	13,613		$	—		$	(58	)		$	13,555		$	13,555		$	—
	31-Dec-12
	(in thousands)
	Securities	Amortized			Gross			Gross				Fair Value			Short-Term			Long Term
		Cost			Unrealized			Unrealized							Investments			Investments
					Gains			Losses
	Mutual Funds	$	27,230		$	11		$	—			$	27,241		$	27,241		$	—
	Totals	$	27,230		$	11		$	—			$	27,241		$	27,241		$	—
	Unrealized losses on investments
	Investments with continuous unrealized losses for less than 12 months and 12 months or greater and their related fair values were as follows:
	30-Sep-13
	(in thousands)
				Less Than 12 Months							12 Months or Greater						Totals
	Securities	Total		Fair			Unrealized				Fair			Unrealized			Total			Total
		number		Values			Losses				Values			Losses			Fair			Unrealized
		in loss															Value			Losses
		position
	Mutual Funds	2		$	13,555		$	(57	)		$	—		$	—		$	13,555		$	(57	)
	Totals	2		$	13,555		$	(57	)		$	—		$	—		$	13,555		$	(57	)
	No unrestricted investments were in a loss position as of December 31, 2012.

Marketable_Securities_Restrict

Marketable Securities - Restricted	9 Months Ended
	Sep. 30, 2013
Marketable Securities, Restricted [Abstract]	'
Marketable Securities - Restricted	'
	Marketable Securities - Restricted
	A Margin Account was established on July 26, 2011 for which the Company needs to pledge, restrict from sale and segregate marketable securities at an approximate ratio of approximately two-to-one, based on the diversity of securities pledged as collateral, for those funds withdrawn and outstanding (see “Note 9 Margin Account Loan”).
	These restricted marketable securities consist of mutual funds. As of September 30, 2013, it was determined that two of the Marketable Securities had other-than-temporary impairments and a loss of $500,000 was recognized. At September 30, 2013, all restricted securities were measured as Level 1 instruments of the fair value measurements standard (see "Note 11: Fair Value").
	Securities classified as restricted from sale consisted of:
	30-Sep-13
	(in thousands)
	Securities	Amortized			Gross			Gross				Fair			Short-Term			Long Term
		Cost			Unrealized			Unrealized				Value			Investments			Investments
					Gains			Losses
	Mutual Funds	$	14,101		$	—		$	(33	)		$	14,068		$	14,068		$	—
	Totals	$	14,101		$	—		$	(33	)		$	14,068		$	14,068		$	—
	31-Dec-12
	(in thousands)
	Securities	Amortized			Gross			Gross				Fair			Short-Term			Long Term
		Cost			Unrealized			Unrealized				Value			Investments			Investments
					Gains			Losses
	Mutual Funds	$	11,050		$	—		$	(54	)		$	10,996		$	10,996		$	—
	Corporate Bonds	3,503			1			—				3,504			3,504			—
	Totals	$	14,553		$	1		$	(54	)		$	14,500		$	14,500		$	—
	Unrealized losses on investments restricted from sale
	Investments restricted from sale with continuous unrealized losses for less than 12 months and 12 months or greater and their related fair values were as follows:
	30-Sep-13
	(in thousands)
				Less Than 12 Months							12 Months or Greater						Totals
	Securities	Total		Fair			Unrealized				Fair			Unrealized			Total			Total
		number		Values			Losses				Values			Losses			Fair			Unrealized
		in loss															Value			Losses
		position
	Mutual Funds	2		$	14,068		$	(33	)		$	—		$	—		$	14,068		$	(33	)
	Totals	2		$	14,068		$	(33	)		$	—		$	—		$	14,068		$	(33	)
	31-Dec-12
	(in thousands)
				Less Than 12 Months							12 Months or Greater						Totals
	Securities	Total		Fair			Unrealized				Fair			Unrealized			Total			Total
		number in		Values			Losses				Values			Losses			Fair			Unrealized
		loss															Value			Losses
		position
	Mutual Funds	1		$	10,996		$	(54	)		$	—		$	—		$	10,996		$	(54	)
	Totals	1		$	10,996		$	(54	)		$	—		$	—		$	10,996		$	(54	)
	Management does not believe any remaining losses represent other-than-temporary impairment based on Management’s evaluation of available evidence as of September 30, 2013.

Accrued_Expenses

Accrued Expenses	9 Months Ended
	Sep. 30, 2013
Accrued Liabilities [Abstract]	'
Accrued Expenses	'
	Accrued Expenses
	Accrued expenses consist of the following:
		(in thousands)
		September 30,		December 31,
		2013		2012
	Compensation	$	338	$	2,131
	Professional fees	464		466
	Other expenses	842		615
	Accrued Alferon production costs	65		70
	Due for returned product	113		113
		$	1,822	$	3,395

Property_and_Equipment

Property and Equipment	9 Months Ended
	Sep. 30, 2013
Property, Plant and Equipment Assets Held-for-sale Disclosure [Abstract]	'
Property and Equipment	'
	Property and Equipment
		(in thousands)
		September 30,			December 31,
		2013			2012
	Land, buildings and improvements	$	4,209		$	4,209
	Furniture, fixtures, and equipment	5,019			4,662
	Leasehold improvements	85			85
	Total property and equipment	9,313			8,956
	Less: accumulated depreciation and amortization	(4,168		)	(3,664		)
	Property and equipment, net	$	5,145		$	5,292
	Property and equipment are recorded at cost. Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the respective assets, ranging from five to thirty-nine years.
	Construction in progress consists of funds used for the construction and installation of property and equipment within the Company's New Brunswick, NJ facility. As of September 30, 2013, construction in progress is reported as $6,970,000 as compared to $6,580,000 as of December 31, 2012. The Company capitalized $130,000 through of September 30, 2013 as interest charges, as compared to $85,000 as of December 31, 2012, which will be expensed proportionately to each long-term asset class of the construction in progress over its respective life.
	The Company owns and operates a 43,000 sq. ft. FDA approved facility in New Brunswick, NJ to produce Alferon® and Ampligen®. In December 2011, our Board of Directors reevaluated the facility enhancement project to focus on upgrading the facility to provide for a high volume, more cost effective manufacturing process for Alferon N Injection®, Alferon® LDO and Ampligen®. The facility enhancement project is currently in the validation phase of the Alferon® manufacturing project as we prepare to undertake the Installation and Operation Qualification phase of the enhancement project. Approximately $7,733,000 has been spent to date through September 30, 2013, as compared to $7,051,000 spent on the project through December 31, 2012, of which $7,051,000 has been financed through a Margin Account with an effective interest rate of approximately 2.50% (see "Note 9: Margin Account Loan"). While the facility is approved by the FDA under the Biological License Application (“BLA”) for Alferon®, this status will need to be reaffirmed upon the completion of the facility's enhancements prior to commercial sale of newly produced inventory product. If and when we obtain a reaffirmation of FDA BLA status and have begun production of new Alferon® API, we will need FDA approval as to the quality and stability of the final product to allow commercial sales to resume. We anticipate that it will take at least until the second half of 2014 before we will have newly produced Alferon® API ready for submission to the FDA for review and approval.

Margin_Account_Loan

Margin Account Loan	9 Months Ended
	Sep. 30, 2013
Margin Account Loan [Abstract]	'
Margin Account Loan	'
	Margin Account Loan
	A “Margin Account” loan was established with Wells Fargo Advisors for which the proceeds of this flexible form of indebtedness effectively serves the Company as a line of credit to finance the capital improvement project underway at the New Brunswick, New Jersey Manufacturing facility. In order to maintain this Margin Account, established on July 26, 2011, the Company needs to pledge, restrict from sale and segregate to a dedicated Margin Account its marketable securities at an approximate ratio of two to one of security collateral to debt undertaken. With the exception of collateral requirements, the Company maintains all the rights and benefits of ownership including receipt of interest, dividends or proceeds from the securities. While this Margin Account has no material establishment or maintenance fees, it currently carries an effective interest rate of approximately 2.5% per annum applied against the “Margin Debit Balance” (i.e., those funds withdrawn and outstanding), based on the prevailing “Wells Fargo Base Rate” less 2.75%. At September 30, 2013, the principal loan balance of the Margin Account was approximately $7,051,000, for which approximately $14,068,000 in Marketable Securities became restricted as dedicated collateral for the indebtedness. For the nine months ended September 30, 2013, the interest charge was approximately $130,000 which has been capitalized along with the other costs related to the capital improvement project (see “Note 6: Marketable Securities – Restricted”).

Stockholders_Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2013
Stockholders' Equity Note [Abstract]	'
Stockholders' Equity	'
	Stockholders’ Equity
	The Equity Incentive Plan of 2009, effective June 24, 2009, authorizes the grant of non-qualified and incentive stock options, stock appreciation rights, restricted stock and other stock awards. A maximum of 15,000,000 shares of common stock is reserved for potential issuance pursuant to awards under the Equity Incentive Plan of 2009. Unless sooner terminated, the Equity Incentive Plan of 2009 will continue in effect for a period of 10 years from its effective date. For the nine months ended September 30, 2013, the Company issued to consultants options and warrants to purchase 2,100,000 shares of common stock that had exercise prices ranging from $0.25 to $0.50 based on the NYSE MKT prices, containing milestone events to achieve vesting and having terms from one to five years. From the Equity Incentive Plan of 2009 through September 30, 2013, the Company issued 11,524,522 securities to Directors and consultants consisting of an aggregate 3,335,152 shares of common stock, and options and warrants to purchase 8,189,370 shares. The shares issued to consultants had prices ranging from $0.20 to $2.30 based on the NYSE MKT closing price.
	The aggregate stock options had various exercise prices ranging from $0.23 to $2.81, had terms of ten years, issued at a premium value of 110% of the NYSE MKT stock closing price and vested over varying periods of time upon grant.
	On July 23, 2012, the Company entered into a new Equity Distribution Agreement (the “New EDA”) with Maxim pursuant to which the Company may sell up to $75,000,000 worth of its shares of Common Stock from time to time through Maxim, as sales agent. Under the New EDA, Maxim is entitled to a fixed commission rate of 4.0% of the gross sales price of Shares sold under the EDA, up to aggregate gross proceeds of $10,000,000, and thereafter, at a fixed commission rate of 3.0% of the gross sales price of Shares sold under the EDA. Sales of the Shares, if any, may be made in transactions that are deemed to be “at-the-market” offerings as defined in Rule 415 under the Securities Act of 1933, as amended, including sales made by means of ordinary brokers' transactions, including on the NYSE MKT, at market prices or as otherwise agreed with Maxim. The Company has no obligation to sell any of the Shares and may at any time suspend offers under the New EDA or terminate the New EDA. The Shares are being sold pursuant to the Company's Universal Shelf Registration Statement on Form S-3, declared effective by the Securities and Exchange Commission on July 2, 2012. On September 14, 2012, the Company filed a Prospectus Supplement with the SEC increasing the number of shares covered by the Prospectus from 12,000,000 to 20,000,000 shares under the New ATM. On October 5, 2012, the Company filed an updated Prospectus Supplement increasing the number of shares covered by the Prospectus to 40,000,000 shares. For the nine months ended September 30, 2013, the Company did not sell any shares pursuant to the ATM. As of December 31, 2012, the Company had sold an aggregate of approximately 29,500,000 shares of the New EDA that resulted in net cash proceeds of approximately $23,003,000 after direct expenses along with commissions paid to Maxim for approximately $820,000.
	The proceeds from this financing are intended to be used to fund infrastructure growth including manufacturing, regulatory compliance and market development.

Fair_Value

Fair Value	9 Months Ended
	Sep. 30, 2013
Fair Value Disclosures [Abstract]	'
Fair Value	'
	Fair Value
	The Company is required under U.S. Generally Accepted Accounting Principles (“GAAP”) to disclose information about the fair value of all the Company’s financial instruments, whether or not these instruments are measured at fair value on the Company’s Consolidated Balance Sheet.
	The Company estimates that the fair values of cash and cash equivalents, other assets, accounts payable and accrued expenses approximate their carrying values due to the short-term maturities of these items.
	The Company also has certain warrants with a cash settlement feature in the unlikely occurrence of a Fundamental Transaction. The fair value recalculation of the Liability resulting from the issuance of the Warrants ("Call") and existence of the Fundamental Transaction ("Put") related to the May 2009 issuance, are calculated using a Monte Carlo Simulation. While the Monte Carlo Simulation is one of a number of possible pricing models, the Company has determined it to be industry accepted and fairly presented the Fair Value of the Warrants. As an additional factor to determine the Fair Value of the Put's Liability, the occurrence probability of a Fundamental Transaction event was factored into the valuation. The Company recomputes the fair value of the Warrants at the end of each quarterly reporting period. Such value computation includes subjective input assumptions that are consistently applied each period. If the Company were to alter its assumptions or the numbers input based on such assumptions, the resulting fair value could be materially different.
	Fair value at September30, 2013, was estimated using the following assumptions:
	Underlying price per share	$0.19 - $0.24
	Exercise price per share	$1.31 - $1.65
	Risk-free interest rate	0.06% - 0.23%
	Expected holding period	0.63 - 1.64 yrs.
	Expected volatility	69.74% - 113.56%
	Expected dividend yield	None
	While the assumptions remain consistent from period to period (e.g., utilizing historical stock prices), the numbers input change from period to period (e.g., the actual historical prices input for the relevant period). The carrying amount and estimated fair value of the above warrants was approximately $66,000 at September 30, 2013. There were no other financial instruments at September 30, 2013.
	On January 1, 2008, the Company adopted new accounting guidance (codified at FASB ASC 820 and formerly Statement No. 157 Fair Value Measurements) that defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles, and expands disclosures about fair value measurements. The guidance does not impose any new requirements around which assets and liabilities are to be measured at fair value, and instead applies to asset and liability balances required or permitted to be measured at fair value under existing accounting pronouncements. The Company measures its warrant liability for those warrants with a cash settlement feature at fair value. As of September 30, 2013, the Company had no derivative assets or liabilities.
	FASB ASC 820-10-35-37 (formerly SFAS No. 157) establishes a valuation hierarchy based on the transparency of inputs used in the valuation of an asset or liability. Classification is based on the lowest level of inputs that is significant to the fair value measurement. The valuation hierarchy contains three levels:
	•	Level 1 – Quoted prices are available in active markets for identical assets or liabilities at the reporting date. Generally, this includes debt and equity securities that are traded in an active market.
	•	Level 2 – Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Generally, this includes debt and equity securities that are not traded in an active market.
	•	Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or other valuation techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation.
	As of September 30, 2013 and 2012, the Company has classified the Warrants with cash settlement features as Level 3. Management evaluates a variety of inputs and then estimates fair value based on those inputs. As discussed above, the Company utilized the Monte Carlo Simulation Model in valuing these Warrants.
	The table below presents the balances of assets and liabilities measured at fair value on a recurring basis by level within the hierarchy as of September 30, 2013:
		(in thousands)
		Total			Level 1			Level 2		Level 3
	Assets:
	Marketable Securities-unrestricted	$	13,555		$	13,555		$	—	$	—
	Marketable Securities-restricted	$	14,068		$	14,068		$	—	$	—
	Liabilities:
	Warrants	$	(66	)	$	—		$	—	$	(66	)
	The changes in Level 3 Liabilities measured at fair value on a recurring basis are summarized as follows:
		Fair Value of Redeemable
		Warrants
		(in thousands)
		2013			2012
	Balance at January 1	$	295		$	380
	Fair value adjustment at March 31	(89		)	151
	Balance at March 31	206			531
	Fair value adjustment at June 30	(102		)	(387		)
	Balance at June 30	104			144
	Fair value adjustment at September 30	(38		)	1,968
	Balance at September 30	$	66		$	2,112

Cash_And_Cash_Equivalents

Cash And Cash Equivalents	9 Months Ended
	Sep. 30, 2013
Cash and Cash Equivalents, at Carrying Value [Abstract]	'
Cash And Cash Equivalents	'
	Cash And Cash Equivalents
	The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents.

Recent_Accounting_Pronouncemen

Recent Accounting Pronouncements	9 Months Ended
	Sep. 30, 2013
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]	'
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	In 2013, the FASB issued Accounting Standards Updates (“ASU”) 2013-01 through 2013-11. In February 2013, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update ("ASU") No. 2013-02, Comprehensive Income (Topic 220): Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income. ASU 2013-02 supersedes and replaces the presentation requirements for amounts reclassified out of Accumulated Other Comprehensive Income in ASU's 2011-05 and 2011-12. This ASU requires an entity to report the effect of significant reclassifications out of Accumulated Other Comprehensive Income on the respective line items in Net Income if the amount being reclassified is required under U.S. Generally Accepted Accounting Principles ("GAAP") to be reclassified in its entirety to Net Income. For other amounts that are not required under GAAP to be reclassified in their entirety to Net Income in the same reporting period, an entity is required to cross-reference other disclosures required under GAAP that provide additional detail about those amounts. Public companies are required to comply with the requirements of AUS 2013-02 for all reporting periods (interim and annual) beginning after December 15, 2012. The adoption of ASU 2013-02 did not have a significant impact on the financial statements.

Funds_Received_From_Sale_Of_In

Funds Received From Sale Of Income Tax Net Operating Losses	9 Months Ended
	Sep. 30, 2013
Income Tax Disclosure [Abstract]	'
Funds Received From Sale Of Income Tax Net Operating Losses	'
	Funds Received From Sale Of Income Tax Net Operating Losses
	As of December 31, 2012, the Company has approximately $119,000,000 of federal net operating loss carryforwards (expiring in the years 2013 through 2032) available to off-set future federal taxable income. The Company also had approximately $36,000,000 of Pennsylvania state net operating loss carryforwards (expiring in the years 2018 through 2032) and approximately $17,000,000 of New Jersey state net operating loss carryforwards (expiring in the years 2030 through 2032) available to off-set future state taxable income.
	In January 2013, the Company effectively sold $8,500,000 of its approximately $17,000,000 of New Jersey state net operating loss carryforwards (for the years 2010 and 2011) for approximately $685,000. The utilization of certain state net operating loss carry-forwards may be subject to annual limitations. With no tax due for the foreseeable future, the Company has determined that the accounting for interest or penalties related to the payment of tax is not necessary at this time.

Subsequent_Events

Subsequent Events	9 Months Ended
	Sep. 30, 2013
Subsequent Events [Abstract]	'
Subsequent Events	'
	Subsequent Events
	During the month of October 2013, we liquidated approximately one-half of the $14,068,000 in Marketable Securities - Restricted (see “Note 6: Marketable Securities – Restricted”) in order to pay-off in its entirety the approximately $7,051,000 of principal balance of the Margin Account Loan (see "Note 9: Margin Account Loan). As a result, the Margin Account Loan was eliminated and the remaining dollar value of the Marketable Securities - Restricted was reclassified to Unrestricted as of October 31, 2013. At September 30, 2013, we recognized $800,000 as other than temporary impairment loss for all of our fixed-income securities (bonds) that were primarily attributable to changes in interest rates and/or a reduction in their rating of credit worthiness as deemed by independent financial rating services and calculated by market price movements. The impact of the October 2013 sales of the Marketable Securities to pay-off the Margin Loan identified a realized loss of approximately $271,000, of which approximately $256,000 had already been recognized as other than temporary impairment loss in September 2013. Management believes that unrealized losses attributed to the Mutual Funds in 2012 and 2013 were limited to temporary impairment based on our evaluation of available evidence as of September 30, 2013 and December 31, 2012.
	The Company evaluated subsequent events through the date on which these financial statements were issued, and with the exception of the above event, determined that no subsequent event constituted a matter that required disclosure or adjustment to the financial statements for the nine months ended September30, 2013.

Net_Loss_Per_Share_Net_Loss_Pe

Net Loss Per Share Net Loss Per Share (Policies)	9 Months Ended
	Sep. 30, 2013
Earnings Per Share [Abstract]	'
Net Loss Per Share Policy	'
	Basic and diluted net loss per share is computed using the weighted average number of shares of common stock outstanding during the period. Equivalent common shares, consisting of stock options and warrants which amounted to 38,421,415 and 33,348,458 shares for the nine months ended September 30, 2013 and 2012, respectively, are excluded from the calculation of diluted net loss per share since their effect is anti-dilutive.

Inventories_Policy

Inventories (Policy)	9 Months Ended
	Sep. 30, 2013
Inventory Disclosure [Abstract]	'
Inventory Policy	'
	The Company uses the lower of first-in, first-out (“FIFO”) cost or market method of accounting for inventory.

Property_and_Equipment_Policie

Property and Equipment (Policies)	9 Months Ended
	Sep. 30, 2013
Property, Plant and Equipment Assets Held-for-sale Disclosure [Abstract]	'
Property, Plant and Equipment, Policy	'
	Property and equipment are recorded at cost. Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the respective assets, ranging from five to thirty-nine years.

Cash_And_Cash_Equivalents_Poli

Cash And Cash Equivalents (Policies)	9 Months Ended
	Sep. 30, 2013
Cash and Cash Equivalents, at Carrying Value [Abstract]	'
Cash and Cash Equivalents, Policy	'
	The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents.

EquityBased_Compensation_Table

Equity-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Weighted Average Assumptions	'
	Accordingly, the fair values of the options granted, were estimated based on the following weighted average assumptions:
		Nine Months Ended September 30,
		2013		2012
	Risk-free interest rate	0.14% - 1.40%		0.68% - 0.86%
	Expected dividend yield	—		—
	Expected lives	1 year - 5 years		5.0 years
	Expected volatility	89.727% - 118.222%		108.76% - 111.95%
	Weighted average grant date fair value for options and warrants issued	$0.14 per option/warrant for 3,870,000 options / warrants		$0.23 per option for 1,499,000 options
Stock Option Activity	'
	Stock option activity for employees:
		Number of			Weighted		Weighted	Aggregate
		Options			Average		Average	Intrinsic
					Exercise		Remaining	Value
					Price		Contractual
							Term
							(Years)
	Outstanding January 1, 2013	9,441,480			$	1.9	5.35	$	—
	Granted	1,170,000			0.36		9.74	—
	Forfeited	—			—		—	—
	Outstanding September 30, 2013	10,611,480			$	1.73	5.17	$	—
	Vested and expected to vest September 30, 2013	10,611,480			$	1.73	5.17	$	—
	Exercisable September 30, 2013	9,798,980			$	1.84	5.02	$	—
	1,170,000 options to purchase shares were granted to employees during the nine months ended September 30, 2013.
	Unvested stock option activity for employees:
		Number of			Weighted		Average	Aggregate
		Options			Average		Remaining	Intrinsic
					Exercise		Contractual	Value
					Price		Term
							(Years)
	Outstanding January 1, 2013	516,373			$	0.45	9.43	$	—
	Granted	882,500			0.27		9.4	—
	Vested	(586,373	)		0.43		9.26	—
	Forfeited	—			—		—	—
	Outstanding September 30, 2013	812,500			$	0.27	8.87	$	—
	Stock option activity for non-employees:
		Number of			Weighted		Weighted	Aggregate
		Options			Average		Average	Intrinsic
					Exercise		Remaining	Value
					Price		Contractual
							Term (Years)
	Outstanding January 1, 2013	3,428,432			$	1.73	4.71	$	—
	Granted	600,000			0.69		9.69	—
	Exercised	—			—		—	—
	Forfeited	(150,000	)		2		—	—
	Outstanding September 30, 2013	3,878,432			$	1.56	5	$	—
	Vested and expected to vest September 30, 2013	3,878,432			$	1.56	5	$	—
	Exercisable September 30, 2013	3,503,432			$	1.93	4.57	$	—
	600,000 options to purchase shares were granted to non-employees during the nine months ended September 30, 2013.
	Unvested stock option activity for non-employees during the year:
		Number of			Weighted		Weighted	Aggregate
		Options			Average		Average	Intrinsic
					Exercise		Remaining	Value
					Price		Contractual
							Term
							(Years)
	Outstanding January 1, 2013	210,422			$	0.4	9.68	$	—
	Options granted	375,000			0.25		9.75	—
	Options vested	(210,422	)		0.4		9.68	—
	Options forfeited	—			—		—	—
	Outstanding September 30, 2013	375,000			$	0.25	9.75	$	—

Inventories_Tables

Inventories (Tables)	9 Months Ended
	Sep. 30, 2013
Inventory Disclosure [Abstract]	'
Schedule of Inventory	'
	Inventories consist of the following:	(in thousands)
		September 30,			December 31,
		2013			2012
	Inventory work-in-process, January 1	$	453		$	897
	Production	5			579
	Spoilage	(458		)	(1,023		)
	Inventory work-in-process, end of period	$	—		$	453

Marketable_Securities_Unrestri1

Marketable Securities - Unrestricted (Tables)	9 Months Ended
	Sep. 30, 2013
Marketable Securities [Abstract]	'
Available for sale securities	'
	Securities classified as available for sale consisted of:
	30-Sep-13
	(in thousands)
	Securities	Amortized			Gross			Gross				Fair Value			Short-Term			Long Term
		Cost			Unrealized			Unrealized							Investments			Investments
					Gains			Losses
	Mutual Funds	$	13,613		$	—		$	(58	)		$	13,555		$	13,555		$	—
	Totals	$	13,613		$	—		$	(58	)		$	13,555		$	13,555		$	—
	31-Dec-12
	(in thousands)
	Securities	Amortized			Gross			Gross				Fair Value			Short-Term			Long Term
		Cost			Unrealized			Unrealized							Investments			Investments
					Gains			Losses
	Mutual Funds	$	27,230		$	11		$	—			$	27,241		$	27,241		$	—
	Totals	$	27,230		$	11		$	—			$	27,241		$	27,241		$	—
Unrealized losses on securities	'
	Investments with continuous unrealized losses for less than 12 months and 12 months or greater and their related fair values were as follows:
	30-Sep-13
	(in thousands)
				Less Than 12 Months							12 Months or Greater						Totals
	Securities	Total		Fair			Unrealized				Fair			Unrealized			Total			Total
		number		Values			Losses				Values			Losses			Fair			Unrealized
		in loss															Value			Losses
		position
	Mutual Funds	2		$	13,555		$	(57	)		$	—		$	—		$	13,555		$	(57	)
	Totals	2		$	13,555		$	(57	)		$	—		$	—		$	13,555		$	(57	)

Marketable_Securities_Restrict1

Marketable Securities - Restricted (Tables)	9 Months Ended
	Sep. 30, 2013
Available for sale securities	'
	Securities classified as available for sale consisted of:
	30-Sep-13
	(in thousands)
	Securities	Amortized			Gross			Gross				Fair Value			Short-Term			Long Term
		Cost			Unrealized			Unrealized							Investments			Investments
					Gains			Losses
	Mutual Funds	$	13,613		$	—		$	(58	)		$	13,555		$	13,555		$	—
	Totals	$	13,613		$	—		$	(58	)		$	13,555		$	13,555		$	—
	31-Dec-12
	(in thousands)
	Securities	Amortized			Gross			Gross				Fair Value			Short-Term			Long Term
		Cost			Unrealized			Unrealized							Investments			Investments
					Gains			Losses
	Mutual Funds	$	27,230		$	11		$	—			$	27,241		$	27,241		$	—
	Totals	$	27,230		$	11		$	—			$	27,241		$	27,241		$	—
Unrealized losses on securities	'
	Investments with continuous unrealized losses for less than 12 months and 12 months or greater and their related fair values were as follows:
	30-Sep-13
	(in thousands)
				Less Than 12 Months							12 Months or Greater						Totals
	Securities	Total		Fair			Unrealized				Fair			Unrealized			Total			Total
		number		Values			Losses				Values			Losses			Fair			Unrealized
		in loss															Value			Losses
		position
	Mutual Funds	2		$	13,555		$	(57	)		$	—		$	—		$	13,555		$	(57	)
	Totals	2		$	13,555		$	(57	)		$	—		$	—		$	13,555		$	(57	)
Restricted Securities [Member]	'
Available for sale securities	'
	Securities classified as restricted from sale consisted of:
	30-Sep-13
	(in thousands)
	Securities	Amortized			Gross			Gross				Fair			Short-Term			Long Term
		Cost			Unrealized			Unrealized				Value			Investments			Investments
					Gains			Losses
	Mutual Funds	$	14,101		$	—		$	(33	)		$	14,068		$	14,068		$	—
	Totals	$	14,101		$	—		$	(33	)		$	14,068		$	14,068		$	—
	31-Dec-12
	(in thousands)
	Securities	Amortized			Gross			Gross				Fair			Short-Term			Long Term
		Cost			Unrealized			Unrealized				Value			Investments			Investments
					Gains			Losses
	Mutual Funds	$	11,050		$	—		$	(54	)		$	10,996		$	10,996		$	—
	Corporate Bonds	3,503			1			—				3,504			3,504			—
	Totals	$	14,553		$	1		$	(54	)		$	14,500		$	14,500		$	—
Unrealized losses on securities	'
	Investments restricted from sale with continuous unrealized losses for less than 12 months and 12 months or greater and their related fair values were as follows:
	30-Sep-13
	(in thousands)
				Less Than 12 Months							12 Months or Greater						Totals
	Securities	Total		Fair			Unrealized				Fair			Unrealized			Total			Total
		number		Values			Losses				Values			Losses			Fair			Unrealized
		in loss															Value			Losses
		position
	Mutual Funds	2		$	14,068		$	(33	)		$	—		$	—		$	14,068		$	(33	)
	Totals	2		$	14,068		$	(33	)		$	—		$	—		$	14,068		$	(33	)
	31-Dec-12
	(in thousands)
				Less Than 12 Months							12 Months or Greater						Totals
	Securities	Total		Fair			Unrealized				Fair			Unrealized			Total			Total
		number in		Values			Losses				Values			Losses			Fair			Unrealized
		loss															Value			Losses
		position
	Mutual Funds	1		$	10,996		$	(54	)		$	—		$	—		$	10,996		$	(54	)
	Totals	1		$	10,996		$	(54	)		$	—		$	—		$	10,996		$	(54	)

Accrued_Expenses_Tables

Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2013
Accrued Liabilities [Abstract]	'
Schedule of Accrued Liabilities	'
	Accrued expenses consist of the following:
		(in thousands)
		September 30,		December 31,
		2013		2012
	Compensation	$	338	$	2,131
	Professional fees	464		466
	Other expenses	842		615
	Accrued Alferon production costs	65		70
	Due for returned product	113		113
		$	1,822	$	3,395

Property_and_Equipment_Tables

Property and Equipment (Tables)	9 Months Ended
	Sep. 30, 2013
Property, Plant and Equipment Assets Held-for-sale Disclosure [Abstract]	'
Property, Plant and Equipment	'
		(in thousands)
		September 30,			December 31,
		2013			2012
	Land, buildings and improvements	$	4,209		$	4,209
	Furniture, fixtures, and equipment	5,019			4,662
	Leasehold improvements	85			85
	Total property and equipment	9,313			8,956
	Less: accumulated depreciation and amortization	(4,168		)	(3,664		)
	Property and equipment, net	$	5,145		$	5,292

Fair_Value_Tables

Fair Value (Tables)	9 Months Ended
	Sep. 30, 2013
Schedule of Assumptions for Fair Value	'
	Fair value at September30, 2013, was estimated using the following assumptions:
	Underlying price per share	$0.19 - $0.24
	Exercise price per share	$1.31 - $1.65
	Risk-free interest rate	0.06% - 0.23%
	Expected holding period	0.63 - 1.64 yrs.
	Expected volatility	69.74% - 113.56%
	Expected dividend yield	None
Schedule of fair value, assets and liabilities measured on recurring basis	'
	The table below presents the balances of assets and liabilities measured at fair value on a recurring basis by level within the hierarchy as of September 30, 2013:
		(in thousands)
		Total			Level 1			Level 2		Level 3
	Assets:
	Marketable Securities-unrestricted	$	13,555		$	13,555		$	—	$	—
	Marketable Securities-restricted	$	14,068		$	14,068		$	—	$	—
	Liabilities:
	Warrants	$	(66	)	$	—		$	—	$	(66	)
Fair Value, Inputs, Level 3 [Member]	'
Fair value, liabilities measured on recurring basis	'
	The changes in Level 3 Liabilities measured at fair value on a recurring basis are summarized as follows:
		Fair Value of Redeemable
		Warrants
		(in thousands)
		2013			2012
	Balance at January 1	$	295		$	380
	Fair value adjustment at March 31	(89		)	151
	Balance at March 31	206			531
	Fair value adjustment at June 30	(102		)	(387		)
	Balance at June 30	104			144
	Fair value adjustment at September 30	(38		)	1,968
	Balance at September 30	$	66		$	2,112

Basis_Of_Presentation_Basis_of

Basis Of Presentation Basis of Presentation (Details)	9 Months Ended
	Sep. 30, 2013
	subsidiary
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Number of domestic subsidiaries (subsidiaries)	3

Net_Loss_Per_Share_Details

Net Loss Per Share (Details)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Earnings Per Share [Abstract]	'	'
Stock options and warrants excluded from calculation of diluted net loss per share (shares)	38,421,415	33,348,458

EquityBased_Compensation_Valua

Equity-Based Compensation (Valuation Assumptions) (Details) (USD $)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Method used	'Black-Scholes-Merton	'
Expected dividend yield (percent)	0.00%	0.00%
Minimum [Member]	'	'
Risk-free interest rate (percent)	0.14%	0.68%
Expected term	'1 year	'5 years
Expected volatility (percent)	89.73%	108.76%
Maximum [Member]	'	'
Risk-free interest rate (percent)	1.40%	0.86%
Expected term	'5 years	'5 years
Expected volatility (percent)	118.22%	111.95%
Weighted Average [Member]	'	'
Weighted average grant date fair value per option (usd per share)	0.14	0.23
Weighted average grant date fair value, options issued (shares)	3,870,000	1,499,000

EquityBased_Compensation_Optio

Equity-Based Compensation (Option Activity) (Details) (USD $)	9 Months Ended			12 Months Ended	9 Months Ended	12 Months Ended	9 Months Ended	12 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2013	Dec. 31, 2012
			Employee Vested Options [Member]	Employee Vested Options [Member]	Employee Nonvested Options [Member]	Employee Nonvested Options [Member]	Nonemployee Vested Options [Member]	Nonemployee Vested Options [Member]	Nonemployee Nonvested Options [Member]	Nonemployee Nonvested Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]	'	'	'	'	'	'	'	'	'	'
Number of options outstanding (shares)	'	'	9,441,480	'	516,373	'	3,428,432	'	210,422	'
Number of options granted (shares)	'	'	1,170,000	'	882,500	'	600,000	'	375,000	'
Number of options vested (shares)	'	'	'	'	-586,373	'	'	'	-210,422	'
Number of options exercised (shares)	'	'	'	'	'	'	0	'	'	'
Number of options forfeited (shares)	'	'	0	'	0	'	-150,000	'	0	'
Number of options outstanding (shares)	'	'	10,611,480	9,441,480	812,500	516,373	3,878,432	3,428,432	375,000	210,422
Number of options vested and expected to vest, outstanding (shares)	'	'	10,611,480	'	'	'	3,878,432	'	'	'
Number of options vested and expected to vest, exercisable (shares)	'	'	9,798,980	'	'	'	3,503,432	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]	'	'	'	'	'	'	'	'	'	'
Weighted Average Exercise Price, Options Outstanding (usd per share)	'	'	$1.90	'	$0.45	'	$1.73	'	$0.40	'
Weighted Average Exercise Price, Options Granted (usd per share)	'	'	$0.36	'	$0.27	'	$0.69	'	$0.25	'
Weighted Average Exercise Price, Options Exercised (usd per share)	'	'	'	'	'	'	$0	'	'	'
Weighted Average Exercise Price, Options Vested (usd per share)	'	'	'	'	$0.43	'	'	'	$0.40	'
Weighted Average Exercise Price, Options Forfeited (usd per share)	'	'	$0	'	$0	'	$2	'	$0	'
Weighted Average Exercise Price, Options Outstanding (usd per share)	'	'	$1.73	$1.90	$0.27	$0.45	$1.56	$1.73	$0.25	$0.40
Weighted Average Exercise Price, Options Vested and Expected to Vest, Outstanding (usd per share)	'	'	$1.73	'	'	'	$1.56	'	'	'
Weighted Average Exercise Price, Options Vested and Expected to Vest, Exercisable (usd per share)	'	'	$1.84	'	'	'	$1.93	'	'	'
Share-based Compensation Arrangement By Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Roll Forward]	'	'	'	'	'	'	'	'	'	'
Weighted Average Remaining Contractual Term (Years), Options outstanding	'	'	'5 years 2 months 2 days	'5 years 4 months 5 days	'8 years 10 months 14 days	'9 years 5 months 5 days	'5 years 0 months 0 days	'4 years 8 months 15 days	'9 years 8 months 29 days	'9 years 8 months 5 days
Weighted Average Remaining Contractual Term (Years), Options Granted	'	'	'9 years 8 months 28 days	'	'9 years 4 months 25 days	'	'9 years 8 months 10 days	'	'9 years 8 months 29 days	'
Weighted Average Remaining Contractual Term (Years), Options Vested	'	'	'	'	'9 years 3 months 4 days	'	'	'	'9 years 8 months 5 days	'
Weighted Average Remaining Contractual Term (Years), Options Exercised	'	'	'	'	'	'	'0 years	'	'	'
Weighted Average Remaining Contractual Term (Years), Options Forfeited	'	'	'0 years	'	'0 years	'	'0 years	'	'0 years	'
Weighted Average Remaining Contractual Term (Years), Options outstanding	'	'	'5 years 2 months 2 days	'5 years 4 months 5 days	'8 years 10 months 14 days	'9 years 5 months 5 days	'5 years 0 months 0 days	'4 years 8 months 15 days	'9 years 8 months 29 days	'9 years 8 months 5 days
Weighted Average Remaining Contractual Term (Years), Options vested and expected to vest	'	'	'5 years 2 months 2 days	'	'	'	'5 years 0 months 0 days	'	'	'
Weighted Average Remaining Contractual Term (Years), Options exercisable	'	'	'5 years 0 months 8 days	'	'	'	'4 years 6 months 27 days	'	'	'
Share-based Compensation Arrangement By Share-based Payment Award, Options, Aggregate Intrinsic Value [Roll Forward]	'	'	'	'	'	'	'	'	'	'
Aggregate Intrinsic Value, Options Outstanding	'	'	$0	'	$0	'	$0	'	$0	'
Aggregate Intrinsic Value, Options Granted	'	'	0	'	0	'	0	'	0	'
Aggregate Intrinsic Value, Options Exercised	'	'	'	'	'	'	0	'	'	'
Aggregate Intrinsic Value, Options Vested	'	'	'	'	0	'	'	'	0	'
Aggregate Intrinsic Value, Options Forfeited	'	'	0	'	0	'	0	'	0	'
Aggregate Intrinsic Value, Options Outstanding	'	'	0	0	0	0	0	0	0	0
Aggregate Intrinsic Value, Options Vested and Expected to Vest, Outstanding	'	'	0	'	'	'	0	'	'	'
Aggregate Intrinsic Value, Options Vested and Expected to Vest, Exercisable	'	'	0	'	'	'	0	'	'	'
Stock issued during period, value	292,000	195,000	'	'	'	'	'	'	'	'
Dilutive securities, effect on basic earnings per share (usd per share)	0	0	'	'	'	'	'	'	'	'
Total compensation cost not yet recognized	$492,000	$308,000	'	'	'	'	'	'	'	'

Inventories_Details

Inventories (Details) (USD $)	9 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Dec. 31, 2012
Inventory Work-in-Process [Roll Forward]	'	'
Inventory, work-in-process, beginning of period	$453	$897
Production	5	579
Spoilage	-458	-1,023
Inventory work-in-process, end of period	$0	$453

Marketable_Securities_Unrestri2

Marketable Securities - Unrestricted (Available for Sale Securities) (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Amortized Cost	$13,613	$27,230
Gross Unrealized Gains	0	11
Gross Unrealized Losses	-58	0
Fair Value	13,555	27,241
Short-Term Investments	13,555	27,241
Long Term Investments	0	0
Mutual Funds [Member]	'	'
Amortized Cost	13,613	27,230
Gross Unrealized Gains	0	11
Gross Unrealized Losses	-58	0
Fair Value	13,555	27,241
Short-Term Investments	13,555	27,241
Long Term Investments	$0	$0

Marketable_Securities_Unrestri3

Marketable Securities - Unrestricted Marketable Securities-Unrealized Losses (Details) (USD $)	1 Months Ended	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
	investment	investment		investment
Schedule of Available-for-sale Securities [Line Items]	'	'	'	'	'
Loss recognized on investments with other than temporary impairments	$800	$800	$0	$800	$0
Total number in loss position (investments)	2	2	'	2	'
Less than twelve months - fair values	13,555	13,555	'	13,555	'
Less than twelve months - unrealized losses	-57	-57	'	-57	'
Twelve months or greater - fair values	0	0	'	0	'
Twelve months or greater - unrealized losses	0	0	'	0	'
Total Fair Value	13,555	13,555	'	13,555	'
Total Unrealized Losses	-57	-57	'	-57	'
Mutual Funds [Member]	'	'	'	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'	'	'	'
Total number in loss position (investments)	2	2	'	2	'
Less than twelve months - fair values	13,555	13,555	'	13,555	'
Less than twelve months - unrealized losses	-57	-57	'	-57	'
Twelve months or greater - fair values	0	0	'	0	'
Twelve months or greater - unrealized losses	0	0	'	0	'
Total Fair Value	13,555	13,555	'	13,555	'
Total Unrealized Losses	-57	-57	'	-57	'
Unrestricted Securities [Member]	'	'	'	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'	'	'	'
Investments with other than temporary impairments (investments)	2	2	'	2	'
Loss recognized on investments with other than temporary impairments	'	$300	'	'	'

Marketable_Securities_Restrict2

Marketable Securities - Restricted (Available for sale securities) (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Amortized Cost	$13,613	$27,230
Gross Unrealized Gains	0	11
Gross Unrealized Losses	-58	0
Marketable securities – restricted	14,068	14,500
Short-Term Investments	13,555	27,241
Long Term Investments	0	0
Restricted Mutual Funds [Member]	'	'
Amortized Cost	14,101	11,050
Gross Unrealized Gains	0	0
Gross Unrealized Losses	-33	-54
Marketable securities – restricted	14,068	10,996
Short-Term Investments	14,068	10,996
Long Term Investments	0	0
Restricted Corporate Bonds [Member]	'	'
Amortized Cost	'	3,503
Gross Unrealized Gains	'	1
Gross Unrealized Losses	'	0
Marketable securities – restricted	'	3,504
Short-Term Investments	'	3,504
Long Term Investments	'	0
Total Restricted Available for Sale Securities [Member]	'	'
Amortized Cost	14,101	14,553
Gross Unrealized Gains	0	1
Gross Unrealized Losses	-33	-54
Marketable securities – restricted	14,068	14,500
Short-Term Investments	14,068	14,500
Long Term Investments	$0	$0

Marketable_Securities_Restrict3

Marketable Securities - Restricted (Unrealized losses on investments restricted from sale) (Details) (USD $)	1 Months Ended	3 Months Ended		9 Months Ended						3 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2013
						Restricted Mutual Funds [Member]	Restricted Mutual Funds [Member]	Total Restricted Available for Sale Securities [Member]	Total Restricted Available for Sale Securities [Member]	Restricted Securities [Member]
						investment	investment	investment	investment	investment
Investments with other than temporary impairments (investments)	'	'	'	'	'	'	'	'	'	2
Total Number in Loss Position (investments)	'	'	'	'	'	2	1	2	1	'
Less than twelve months - fair values	$13,555	$13,555	'	$13,555	'	$14,068	$10,996	$14,068	$10,996	'
Less than twelve months - unrealized losses	-57	-57	'	-57	'	-33	-54	-33	-54	'
Twelve months or greater - fair values	0	0	'	0	'	0	0	0	0	'
Twelve months or greater - unrealized losses	0	0	'	0	'	0	0	0	0	'
Total Fair Value	13,555	13,555	'	13,555	'	14,068	10,996	14,068	10,996	'
Total Unrealized Losses	-57	-57	'	-57	'	-33	-54	-33	-54	'
Loss recognized on investments with other than temporary impairments	$800	$800	$0	$800	$0	'	'	'	'	$500

Accrued_Expenses_Details

Accrued Expenses (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Accrued Liabilities [Abstract]	'	'
Compensation	$338	$2,131
Professional fees	464	466
Other expenses	842	615
Accrued Alferon production costs	65	70
Due for returned product	113	113
Total Accrued Expenses	$1,822	$3,395

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	9 Months Ended	12 Months Ended	13 Months Ended	19 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Dec. 31, 2012	Dec. 31, 2012	Jun. 30, 2013
	sqft
Property, Plant and Equipment [Line Items]	'	'	'	'
Property, Plant and Equipment, Gross	$9,313	$8,956	$8,956	'
Less: accumulated depreciation and amortization	-4,168	-3,664	-3,664	'
Property and equipment, net	5,145	5,292	5,292	'
Construction in progress	6,970	6,580	6,580	'
Capitalized interest charges	130	85	'	'
Area of facility (square feet)	43,000	'	'	'
Construction and development costs	'	'	7,051	7,733
Margin account loan	7,051	7,051	7,051	'
Interest rate during period (percent)	2.50%	'	2.50%	'
Land, buildings and improvements [Member]	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'
Property, Plant and Equipment, Gross	4,209	4,209	4,209	'
Furniture, fixtures, and equipment[Member]	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'
Property, Plant and Equipment, Gross	5,019	4,662	4,662	'
Leasehold improvements [Member]	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'
Property, Plant and Equipment, Gross	$85	$85	$85	'
Minimum [Member]	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'
Useful life	'5 years	'	'	'
Maximum [Member]	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'
Useful life	'39 years	'	'	'

Margin_Account_Loan_Details

Margin Account Loan (Details) (USD $)	9 Months Ended	13 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Dec. 31, 2012
Margin Account Loan [Abstract]	'	'
Line of credit facility initiation date	26-Jul-11	'
Interest rate during period (percent)	2.50%	2.50%
Reduction in Wells Fargo base rate (percent)	2.75%	'
Margin account loan liability	$7,051	$7,051
Marketable securities – restricted	14,068	14,500
Increase in accrued interest	$130	'

Stockholders_Equity_Details

Stockholders' Equity (Details) (USD $)	9 Months Ended
	Sep. 30, 2013
Award requisite service period	'10 years
Exercise price range, lower range limit (usd per share)	$0.23
Exercise price range, upper range limit (usd per share)	$2.81
Award vesting period	'0 years
Stock Options [Member]	'
Purchase price premium (percent)	110.00%
Equity Incentive Plan of 2009 [Member]	'
Date established	24-Jun-09
Number of shares authorized (shares)	15,000,000
Equity Incentive Plan of 2009 [Member] | Consultants [Member]	'
Award requisite service period	'10 years
Number of options granted (shares)	2,100,000
Exercise price range, lower range limit (usd per share)	$0.25
Exercise price range, upper range limit (usd per share)	$0.50
Equity Incentive Plan of 2009 [Member] | Consultants [Member] | Maximum [Member]	'
Award vesting period	'5 years
Equity Incentive Plan of 2009 [Member] | Consultants [Member] | Minimum [Member]	'
Award vesting period	'1 year
Equity Incentive Plan of 2009 [Member] | Directors and consultants [Member]	'
Number of options granted (shares)	11,524,522
Exercise price range, lower range limit (usd per share)	$0.20
Exercise price range, upper range limit (usd per share)	$2.30
Equity Incentive Plan of 2009 [Member] | Directors and consultants [Member] | Stock Options [Member]	'
Number of options granted (shares)	8,189,370
Equity Incentive Plan of 2009 [Member] | Directors and consultants [Member] | Common Class A [Member]	'
Number of options granted (shares)	3,335,152

Stockholders_Equity_Equity_Dis

Stockholders' Equity (Equity Distribution Agreement) (Details) (USD $)	9 Months Ended		0 Months Ended	9 Months Ended	0 Months Ended
	Sep. 30, 2013	Sep. 30, 2013	Oct. 05, 2012	Sep. 30, 2013	Sep. 14, 2012	Sep. 14, 2012
		Shares Sold In Current Period [Member]	Maxim 2012 Agreement [Member]	Maxim 2012 Agreement [Member]	Minimum [Member]	Maximum [Member]
					Maxim 2012 Agreement [Member]	Maxim 2012 Agreement [Member]
Maximum dollar amount of shares under the EDA	'	'	'	$75,000,000	'	'
Fixed commission rate for gross proceeds $10,000,000 or less (percent)	'	'	'	4.00%	'	'
Gross proceeds from common stock, threshold	10,000,000	'	'	'	'	'
Fixed commission rate for gross proceeds in excess of $10,000,000 (percent)	'	'	'	3.00%	'	'
Number of shares to be sold under the equity distribution agreement	'	'	40,000,000	'	12,000,000	20,000,000
Number of shares sold under equity distribution agreement	'	0	'	29,500,000	'	'
Cash proceeds from shares sold under equity distribution agreement	'	0	'	23,003,000	'	'
Commissions paid on shares sold under equity distribution agreement	'	'	'	$820,000	'	'

Fair_Value_Fair_Value_Assumpti

Fair Value (Fair Value Assumptions) (Details) (USD $)	9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2013
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'
Expected dividend yield (usd per share)	$0
Minimum [Member]	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'
Underlying price per share (usd per share)	$0.19
Exercise price per share (usd per share)	$1.31
Risk-free interest rate (percent)	0.06%
Expected holding period	'0 years 7 months 17 days
Expected volatility (percent)	69.74%
Maximum [Member]	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'
Underlying price per share (usd per share)	$0.24
Exercise price per share (usd per share)	$1.65
Risk-free interest rate (percent)	0.23%
Expected holding period	'1 year 7 months 19 days
Expected volatility (percent)	113.56%
Warrant [Member]	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'
Liabilities, fair value disclosure	$66

Fair_Value_Assets_and_Liabilit

Fair Value (Assets and Liabilities Measured on a Recurring Basis) (Details) (USD $)	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2011
In Thousands, unless otherwise specified
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'	'	'	'	'	'
Marketable securities – unrestricted	$13,555	'	'	$27,241	'	'	'	'
Marketable securities – restricted	14,068	'	'	14,500	'	'	'	'
Redeemable warrants	-66	'	'	-295	'	'	'	'
Fair Value, Inputs, Level 1 [Member]	'	'	'	'	'	'	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'	'	'	'	'	'
Marketable securities – unrestricted	13,555	'	'	'	'	'	'	'
Marketable securities – restricted	14,068	'	'	'	'	'	'	'
Redeemable warrants	0	'	'	'	'	'	'	'
Fair Value, Inputs, Level 2 [Member]	'	'	'	'	'	'	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'	'	'	'	'	'
Marketable securities – unrestricted	0	'	'	'	'	'	'	'
Marketable securities – restricted	0	'	'	'	'	'	'	'
Redeemable warrants	0	'	'	'	'	'	'	'
Fair Value, Inputs, Level 3 [Member]	'	'	'	'	'	'	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'	'	'	'	'	'
Marketable securities – unrestricted	0	'	'	'	'	'	'	'
Marketable securities – restricted	0	'	'	'	'	'	'	'
Redeemable warrants	-66	'	'	'	'	'	'	'
Warrant [Member] | Fair Value, Inputs, Level 3 [Member]	'	'	'	'	'	'	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'	'	'	'	'	'
Redeemable warrants	-66	-104	-206	-295	-2,112	-144	-531	-380
Warrant [Member] | Change During Period [Member]	'	'	'	'	'	'	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'	'	'	'	'	'
Redeemable warrants	$38	$102	$89	'	($1,968)	$387	($151)	'

Funds_Received_From_Sale_Of_In1

Funds Received From Sale Of Income Tax Net Operating Losses (Details) (USD $)

1 Months Ended

3 Months Ended

9 Months Ended

1 Months Ended

12 Months Ended

Jan. 31, 2013

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2012

Dec. 31, 2012

Jan. 31, 2013

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Internal Revenue Service (IRS) [Member]

Pennsylvania [Member]

New Jersey [Member]

New Jersey [Member]

Minimum [Member]

Minimum [Member]

Minimum [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

Internal Revenue Service (IRS) [Member]

Pennsylvania [Member]

New Jersey [Member]

Internal Revenue Service (IRS) [Member]

Pennsylvania [Member]

New Jersey [Member]

Operating Loss Carryforwards [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Operating loss carryforwards

'

'

'

'

'

$119,000,000

$36,000,000

'

$17,000,000

'

'

'

'

'

'

Operating loss carryforwards, expiration dates

'

'

'

'

'

'

'

'

'

'2013

'2018

'2030

'2032

'2032

'2032

Operating loss carryforwards, amount of NOL carryforwards sold

'

'

'

'

'

'

'

8,500,000

'

'

'

'

'

'

'

Funds received from sale of income tax net operating losses

$685,000

$0

$0

$686,000

$1,328,000

'

'

'

'

'

'

'

'

'

'

Subsequent_Events_Subsequent_E

Subsequent Events Subsequent Events (Details) (USD $)	1 Months Ended	3 Months Ended		9 Months Ended					1 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Dec. 31, 2012	Oct. 31, 2013	Oct. 31, 2013	Sep. 30, 2013
						Total Restricted Available for Sale Securities [Member]	Total Restricted Available for Sale Securities [Member]	Total Restricted Available for Sale Securities [Member]	Margin Loan [Member]	Margin Loan [Member]
								Subsequent Event [Member]	Subsequent Event [Member]	Subsequent Event [Member]
Subsequent Event [Line Items]	'	'	'	'	'	'	'	'	'	'
Marketable Securities-Restricted	$13,555	$13,555	'	$13,555	'	$14,068	$10,996	$14,068	'	'
Extinguishment of debt amount	'	'	'	'	'	'	'	'	7,051	'
Loss recognized on investments with other than temporary impairments	800	800	0	800	0	'	'	'	'	'
Realized loss on sale of marketable securities	'	'	'	'	'	'	'	'	$271	$256